Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales by Bullement, A. et al.
This is a repository copy of Cost-effectiveness of trifluridine/tipiracil for previously treated 
metastatic colorectal cancer in England and Wales.




Bullement, A. orcid.org/0000-0001-7091-0972, Underhill, S., Fougeray, R. et al. (1 more 
author) (2018) Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic 






This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Original Study
Cost-effectiveness of Trifluridine/tipiracil for
Previously Treated Metastatic Colorectal Cancer
in England and Wales
Ash Bullement,1 Stuart Underhill,2 Ronan Fougeray,3 Anthony James Hatswell1,4
Abstract
A cost-effectiveness model predicting the outcomes of treatment with trifluridine/tipiracil based on the results
of the randomised controlled trials conducted for regulatory agencies. The results demonstrate improved
outcomes compared to standard care and improved outcomes and lower cost (dominance) compared to
regorafenib.
Background: Treatment options at third-line and beyond for patients with late-line metastatic colorectal cancer
(mCRC) are limited, and outcomes are poor with best supportive care (BSC). This study investigated the cost-
effectiveness of trifluridine/tipiracil and regorafenib relative to BSC alone in patients with mCRC who have been
previously treated with, or are not considered candidates for, standard chemotherapies. Materials and Methods: A
partitioned survival model was constructed to assess the lifetime costs and benefits accrued by patients. Clinical data
were derived from the pivotal phase III (Randomized, Double-Blind, Phase 3 Study of TAS-102 plus Best Supportive
Care [BSC] versus Placebo plus BSC in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemo-
therapies [RECOURSE]) and supporting phase II (J003-10040030) randomized controlled trial of trifluridine/tipiracil þ
BSC versus placebo þ BSC, as well as the phase III Colorectal Cancer Treated With Regorafenib or Placebo After
Failure of Standard Therapy (CORRECT) randomized controlled trial of regorafenib, and were extrapolated to estimate
lifetime outcomes. Costs were taken from published sources, and health effects sourced from previous mCRC
studies. Results: Trifluridine/tipiracil was associated with a 0.27 incremental life year versus BSC alone, which cor-
responds to a 0.17 quality-adjusted life year gain. The incremental cost of treatment with trifluridine/tipiracil was
£8,479, resulting in an incremental cost-effectiveness ratio of £51,194 per quality-adjusted life year gained. Trifluridine/
tipiracil was shown to dominate regorafenib (improve outcomes with reduced costs). Sensitivity analyses showed
principal areas of uncertainty were survival estimates and patient utility. Conclusions: The results show that tri-
fluridine/tipiracil is more clinically and cost-effective than regorafenib, with clinical outcomes greatly exceeding those
for patients treated with BSC alone. Based on the results of the analysis, trifluridine/tipiracil offers an important new
treatment option for patients with mCRC maintaining good performance status at the end of life.
Clinical Colorectal Cancer, Vol. 17, No. 1, e143-51 ª 2017 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Metastatic colorectal cancer (mCRC) is the second most com-
mon cause of cancer-related death in the United Kingdom (UK).1,2
Five-year survival rates for UK patients with mCRC are notably
lower than those in many other countries, including Canada,
Australia, Sweden, and Norway.3 Survival rates are particularly poor
in late-line disease, that is, for patients who have progressed on
available first- or second-line treatments, and expected survival with
no active pharmacologic treatment is approximately 6 months. As
such, this poor prognosis designates mCRC as an “end of life”
disease (ie, patients are entering their final year of life).4-7
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Trifluridine/tipiracil (Lonsurf, Servier) is a chemotherapy indicated
for the treatment of adult patients with mCRC who have been pre-
viously treated with, or are not considered candidates for, available
therapies including: fluoropyrimidine-, oxaliplatin-, and irinotecan-
based chemotherapies; anti-vascular endothelial growth factor agents;
and anti-epidermal growth factor receptor agents which are only used
in Kirsten rat sarcoma viral oncogene homolog wild-type patients.8
Clinical trial data from the primary analysis cut-off date (after the
571st death) of the placebo-controlled phase III Randomized, Double-
Blind, Phase 3 Study of TAS-102 plus Best Supportive Care [BSC]
versus Placebo plus BSC in Patients with Metastatic Colorectal Cancer
Refractory to Standard Chemotherapies (RECOURSE) study
demonstrated an increase in median overall survival (OS) of 1.8
months (7.1 vs. 5.3 months) for trifluridine/tipiracil (hazard ratio
[HR], 0.68; 95% confidence interval [CI], 0.58-0.81; P < .001).4
Follow-up data from RECOURSE provided additional informa-
tion on the primary endpoint of OS, with the median survival gain
extending to 2.0 months (7.2 vs. 5.2 months) for trifluridine/tipiracil
(HR, 0.69; 95% CI, 0.59-0.81; P < .0001).9 Similar results were
also observed in the phase II trial used for registration in Japan, with
an increase in median OS of 2.4 months (9.0 vs. 6.6 months) for
trifluridine/tipiracil (HR, 0.56; 95% CI, 0.39-0.81; P ¼ .0011).5
Regorafenib (Stivarga, Bayer) is an oral multi-kinase inhibitor
indicated for the treatment of adult patients with mCRC who have
been previously treated with, or are not considered candidates for,
available therapies including a fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapies, an anti-vascular endothelial
growth factor therapy, and an anti-epidermal growth factor receptor
therapy.10 Clinical trial data from the placebo-controlled phase III
Colorectal Cancer Treated With Regorafenib or Placebo After
Failure of Standard Therapy (CORRECT) study demonstrated an
increase in median OS of 1.4 months (6.4 vs. 5.0 months) for
regorafenib (HR, 0.77; 95% CI, 0.64-0.94; P ¼ .0052).11
Trifluridine/tipiracil was recently approved for use through the
UK National Health Service (NHS) following positive recommen-
dation from the National Institute for Health and Care Excellence
(NICE).12 Prior to the introduction of trifluridine/tipiracil, NHS
patients with late-line disease had no active treatment options
available as regorafenib is not currently recommended for use in the
UK, although it is available in many European countries.13-16
The objective of this study was to estimate the cost-effectiveness
of trifluridine/tipiracil compared with other available treatment
options for patients at this line (ie, best supportive care [BSC] and
regorafenib) from a UK NHS perspective.
Materials and Methods
Model
A partitioned survival (also known as an “area under the curve”)
cost-utility model was constructed in Microsoft Excel. A partitioned
survival model calculates the proportion of patients by progression
status (that is, those patients in pre- and post-progression) at a given
time point based on survival curves, and uses these proportions to
inform the benefits accrued and costs incurred over the time horizon
of the model.
The model utilizes a standard 3-state structure of pre-progression
survival, post-progression survival, and death. This structure was
chosen based on its wide use in previous UK health technology
appraisal submissions in cancer.17-19 The model structure is pre-
sented in Figure 1.
A 10-year time horizon was used in the model (ie, costs and
outcomes for patients were considered up until 10 years after the
initiation of treatment). This time horizon was assumed to reflect
patient lifetime as the model predicted that, by this time, over 99%
of patients had died in each treatment arm, and further extrapola-
tion of model results was deemed unnecessary for decision-making.
Outcomes in the model were presented in the form of costs, life
years (LYs), and quality-adjusted life years (QALYs). QALYs are a
combined outcome to describe accrued treatment benefit that takes
into account both the length of life (presented as LYs) and the
health-related quality of life (HRQL), by adjusting the length of life
according to derived HRQL.
Costs and QALYs were discounted at an annual rate of 3.5%, in
line with NICE guidance.20 Discounting is included within eco-
nomic modeling based on the principle that, generally, people prefer
to receive goods and services now rather than later (also known as
‘time preference’).21
Efficacy and Safety
Efficacy and safety data for trifluridine/tipiracil and BSC used in
the model were derived from the pivotal phase III RECOURSE
trial4 and the supporting Japanese phase II registration trial.5 Both
trials were multicenter, double-blind, randomized (2:1), placebo-
controlled studies on the efficacy and safety of trifluridine/tipir-
acil.4,5 Owing to similarities in the trial protocols, both were
deemed appropriate for inclusion in the model. Following the
publication of the phase III RECOURSE trial, follow-up data were
made available for the efficacy outcomes of OS and progression-free
survival (PFS), which was consequently used to inform the model as
the follow-up data provided more complete information on both
OS and PFS outcomes.9
Efficacy outcomes from the 2 trifluridine/tipiracil trials were
pooled using 2 methods: naive pooling (ie, breaking randomization)
and study-stratified pooling (ie, preserving randomization), both of
which yielded similar outcomes compared with BSC. For OS, naive
pooling yielded an HR of 0.67 (95% CI, 0.58-0.78; P < .001), and
study-stratified pooling also yielded an HR of 0.67 (95% CI, 0.58-
0.77; P < .001). For PFS, naive pooling yielded an HR of 0.46
(95% CI, 0.40-0.53; P < .001), and study-stratified pooling yielded
an HR of 0.47 (95% CI, 0.40-0.54; P < .001). As both methods
produced very similar results, naive pooling was deemed appropriate
Figure 1 Model Schematic. Note: Arrows Represent Possible
Transitions Through the Model Health States
Pre-progression Post-progression
Death
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and consequently used to inform the model (as this methodology
reduced the complexity of the analysis).
Parametric survival curve fitting was subsequently performed on
pooled OS and PFS data according to NICE guidance,22 as this
allowed for outcomes to be modeled beyond the observed data (also
referred to as extrapolation beyond the duration of the study). By
the end of follow-up in both trials, the pooled data showed that
86.1% of patients had died, and 91.5% of patients had either
progressed or died. Consequently, minimal extrapolation was
required to establish estimates of long-term outcomes.
For patients treated with regorafenib, efficacy data from the
placebo-controlled phase III CORRECT trial publication by Gro-
they et al were used to inform the model.11 The HRs against pla-
cebo for the OS and PFS curves from both this trial and the phase
III RECOURSE trial were used to elicit an indirect comparison of
trifluridine/tipiracil and regorafenib using the Bucher method.19
To account for toxicity, all common adverse events (AEs)
recorded in the RECOURSE study were included in the model, and
were pooled with equivalent AE rates recorded in the phase II
study.4,5 AEs were classified as common if they occurred in 10% or
more of patients, and were seen in a higher proportion of patients
receiving trifluridine/tipiracil compared with BSC.23 The
RECOURSE study showed that trifluridine/tipiracil was associated
with few serious AEs, and of these, neutropenia was the most
frequently observed.23
AE rates for regorafenib were sourced directly from the COR-
RECT study.11 The CORRECT study showed that regorafenib was
also associated with few serious AEs, with hand-foot skin reaction
being the most frequently observed.
Naively comparing AE rates across studies relies on the assump-
tion of direct comparability between the study populations, and the
associated assessment of AEs within the studies. Given that the
studies were performed under different conditions and in non-
identical populations, the generalizability of the toxicity profiles
across studies is questionable. The rapporteur from the Committee
for Medicinal Products for Human Use (CHMP) stated that
“Overall, the toxicity of trifluridine/tipiracil is considered manageable
and is not considered worse than the safety profile of regorafenib.”24
Therefore, results regarding the relative toxicity profiles of regor-
afenib and trifluridine/tipiracil should be interpreted with caution.
Treatment Cost and Posology
Trifluridine/tipiracil is available in a variety of pack sizes, ranging
from a 20-pack of 15 mg tablets priced at £500.00, to a 60-pack of
20 mg tablets priced at £2000.00; equivalent to a cost per milligram
of £1.67 (prices correct at time of print).25 Treatment is adminis-
tered on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long
as benefit is observed or until unacceptable toxicity occurs.8
Trifluridine/tipiracil is dosed according to body surface area
(BSA), as stated in the summary of product characteristics (SPC).8
The distribution of patient BSA was derived using patient-level data
from the pooled clinical trials. The use of patient-level data accounts
for patients receiving the range of doses of trifluridine/tipiracil
specified in the SPC, as considering only the mean dose would
introduce bias owing to the skewed distribution of BSA.
A log-normal curve was fitted to the distribution of patient BSA
from the pooled data (to ensure consistency with the efficacy data),
based on previous work by Porter et al, who showed the log-normal
distribution to be a good fit to BSA from Health Survey for England
data.26 The average BSA of the pooled population was 1.75 m2,
which is notably lower than the mean BSA reported by Porter et al
for the UK general population (approximately 1.88 m2). The use of
lower BSA for patients with late-line mCRC compared with the
general population was validated by clinicians at both an advisory
board meeting in January 2016 and at the NICE appraisal com-
mittee meeting for trifluridine/tipiracil,12 as it would be expected
that patients with late-line mCRC weigh less than the general
population owing to disease-related weight loss.
Dosing adjustments for patients treated with trifluridine/tipiracil
may be required based on individual safety and tolerability.8 A
maximum of 3 dose reductions are permitted for patients treated
with trifluridine/tipiracil, as indicated in the SPC. Therefore, within
the model, the proportion of patients experiencing a dose reduction
in each of the first 3 model cycles were allocated the next largest
dose available, assuming that the proportion of dose reductions was
linear across all BSA categories.
Regorafenib is available in an 84-pack of 40 mg tablets priced at
£3744.00; equivalent to a cost per tablet of £44.57.25 Treatment is
administered on Days 1 to 21 of a 28-day treatment cycle as long as
benefit is observed or until unacceptable toxicity occurs. In the
model, regorafenib is dosed at 160 mg once daily, as per the SPC,10
with treatment assumed to continue until progression or death
(in the absence of time on treatment data).
Health Outcomes
HRQL data were required for use in the model to ascertain the
impact of treatment and progression status on patient utility. Utility
values are numerical values that reflect an individual’s preferences
for different health outcomes, measured on an interval scale with
0 reflecting states of health equivalent to death and 1 reflecting
perfect health.27 These utility values are used to adjust LYs gained in
order to produce the outcome of QALYs in the model.
Neither of the trifluridine/tipiracil studies directly considered the
HRQL of patients; however, the CORRECT study of regorafenib
included the EuroQol EQ-5D-3L index questionnaire and visual
analog scale.11 We used utilities derived from the index scale
measure in our model in line with NICE guidance, which states that
“the EQ-5D is the preferred measure of health-related quality of life
in adults.”20 EQ-5D-3L utilities from the CORRECT study were
reported as 0.73 and 0.74 for patients who received regorafenib plus
BSC and placebo plus BSC, respectively, at baseline, and 0.59 for
both patient groups at the end of treatment. These utility values
were used to directly inform patient HRQL in each of the model
health states considered (as shown in Figure 1), by applying the
baseline values for pre-progressive patients and the post-treatment
values for patients in post-progressive disease (after which all
patients discontinue treatment).
Utility values from the CORRECT study implied a small
disutility (0.01) for patients who have not yet progressed and are
actively receiving treatment with regorafenib, which we applied in
our model to account for the potential decrement in HRQL asso-
ciated with receiving active treatment with either trifluridine/tipir-
acil or regorafenib (ie, HRQL decrements attributable to toxicity). A
disutility attributable to active treatment was used owing to the lack
Ash Bullement et al
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of data available to inform AE-specific utility decrements (ie, re-
ductions in health utility owing to the occurrence of AEs), and was
assumed to be reasonable given the non-inferior safety profile of
trifluridine/tipiracil compared with regorafenib.24
Medical Resource Use (MRU)
MRU was estimated by clinical experts in the treatment of
colorectal cancer because, given the lack of treatment options, data
regarding resource use estimates for patients with late-line mCRC
are scarcely reported. Initial estimates were based on the MRU for
patients at earlier lines of therapy (taken from the previous manu-
facturers’ submissions to NICE of cetuximab, bevacizumab, and
panitumumab for the treatment of mCRC after first-line chemo-
therapy).7 These estimates were reviewed and updated by clinical
experts to reflect the anticipated MRU of patients eligible for tri-
fluridine/tipiracil and regorafenib (and also those who would receive
BSC at this line of disease).
The cost of treating AEs was applied in the model as a lump sum
upon initiation of treatment, and was calculated as £730.82,
£103.50, and £349.51 for patients receiving trifluridine/tipiracil,
BSC, and regorafenib, respectively. Costs were calculated based on
NHS reference costs for specific AEs, taking into account the fre-
quency of occurrence. Of note, the cost of treating AEs for patients
receiving regorafenib was calculated at a lower cost compared with
patients receiving trifluridine/tipiracil owing to the difference in
treatment setting and associated costs for the different AEs experi-
enced across treatment arms.
End of life care was associated with a cost taken from a cancer-
specific study into the cost of end-of-life care by Round et al, and
was applied as a lump sum upon death.28 The study considered the
cost of health, social, charity, and informal care for patients with
lung, breast, colorectal, and prostate cancer at the end of life in
England and Wales. From this study, the colorectal cancer-specific
cost of health, social, and charity care, £6343, was used to inform
our model; the cost of informal care (£2850) is not included in
NICE calculations of the cost per QALY and was therefore omitted
from our model.
All MRU estimates and their associated costs are presented in
Table 1.
Validation
Throughout development, the model underwent a number of
validation processes. A full technical review was performed by an
independent economic expert who was involved in the NICE
reviews of cetuximab and panitumumab for the treatment of first-
line mCRC.29 Following this, the model was subject to review
from an advisory board of both health economic and clinical experts
held in January, 2016. The model was also critiqued by an inde-




Following NICE guidance on survival curve fitting to patient-
level data, the statistical and visual goodness of fit were analyzed
for potential candidate curves. From Akaike information criterion
scores, a log-logistic curve stratified by treatment group was
identified as the best fit for both OS and PFS, which also appeared
to fit well visually. The 5-year OS for patients using this curve was
1.4% and 0.6% for trifluridine/tipiracil and BSC, respectively.
These estimates were deemed acceptable by clinical experts on the
advisory board.
HRs derived using the Bucher method of indirect comparison for
trifluridine/tipiracil versus regorafenib were 0.88 (95% CI, 0.68-
1.14) for OS and 0.98 (95% CI, 0.78-1.23) for PFS. These HRs
were subsequently applied in the model to derive estimates for the
relative efficacy of regorafenib versus both trifluridine/tipiracil and
BSC.
A plot of the resultant curves used for OS and PFS for all
treatment options, along with the Kaplan-Meier curves from trial
data is shown in Figure 2. The figure shows the expected OS and
PFS for patients over time, with the curve fits providing extrapo-
lation beyond the duration of the studies and the Kaplan-Meier
curves showing the survival outcomes observed within the dura-
tion of the studies. A summary of the validation of clinical outcome
results is presented in Table 2.
Model Outcomes
Model outcomes were costs, LYs, and QALYs for each treatment
arm. From these, incremental costs and QALYs were used to pro-
duce the incremental cost-effectiveness ratio (also known as the cost
per QALY gained), which is NICE’s preferred measure of cost-
effectiveness.31 Results presented in this paper are probabilistic, as
these results capture the uncertainty attributable to individual
model parameters. Mean values as well as percentiles from 5000
model runs are presented to demonstrate uncertainty in the calcu-
lated costs, QALYs, and LYs.
In addition, the results include the probability of the pharma-
ceutical interventions (trifluridine/tipiracil and regorafenib)
Table 1 Medical Resource Use Estimates










Oral chemotherapy day casea 1.00 £192
Medical oncologist 1.00 £171




Health home visitor 0.25 0.25 1.00 £44
District nurse 1.00 £44
GP surgery visit 1.00 £37
Other Resource Use
Resource T/T Rego BSC All
Adverse event costs £731 £350 £104
End of life care £6343
Abbreviations: BSC ¼ best supportive care; GP ¼ general practitioner; MRU ¼ medical
resource use; Rego ¼ regorafenib; T/T ¼ trifluridine/tipiracil.
aPatients that experience a dose reduction incur the cost of an additional oral chemotherapy day
case.
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providing a mean extension in survival of at least 3 months. This
outcome was deemed of particular interest in the context of decision
making, as fulfilment of this criterion qualifies the treatment for
special consideration as for end-of-life drugs (the other criterion
being that life expectancy is expected to be less than 24 months in
the absence of treatment).32
Base-case Results
BSC alone is associated with costs of £9499, 0.66 Lys, and 0.40
QALYs. Trifluridine/tipiracil is associated with costs of £17,978,
0.92 Lys, and 0.57 QALYs. Regorafenib is associated with costs of
£24,112, 0.82 Lys, and 0.51 QALYs. Compared with BSC alone,
trifluridine/tipiracil is associated with an LY gain (LYG) of 0.26,
incremental QALY gain of 0.17, and incremental costs of £8479 per
patient, resulting in an incremental cost-effectiveness ratio of
£51,194 per QALY gained. Probabilistic analysis (accounting for
the uncertainty in estimates) indicates trifluridine/tipiracil is asso-
ciated with a 61.0% probability of providing an extension in life
beyond 3 months compared with BSC alone.
Compared with BSC alone, regorafenib is associated with a 0.16
LYG, incremental QALY gain of 0.11, and incremental costs of
£14,613. Regorafenib is associated with a 22.5% probability of
providing an extension in life beyond 3 months compared with BSC
alone.
Compared with regorafenib, trifluridine/tipiracil is associated with a
0.10 LYG, incrementalQALY gain of 0.06, and a cost saving of £6134,
and therefore, trifluridine/tipiracil dominates regorafenib (ie, increased
expected benefit for reduced expected cost). Results comparing regor-
afenib with either BSC or trifluridine/tipiracil were associated with
considerably more uncertainty than the comparison between BSC and
trifluridine, largely driven by the lack of head-to-head data available.
Full pairwise results are summarized in Table 3.
Figure 2 Efficacy Curves for All Treatments
Abbreviations: BSC ¼ Best supportive care; OS ¼ overall survival; PFS ¼ progression-free survival; Rego ¼ regorafenib; T/T ¼ trifluridine/tipiracil.
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Sensitivity Analysis
Following the production of these headline model results, key
areas of the model were explored via a sensitivity analysis, where
aspects of the model were varied using alternative model settings.
The results of the sensitivity analysis performed in the model are
presented in Table 4.
The results demonstrate that the main areas of model uncertainty
are attributable to the source of, and statistical fit to, efficacy data for
trifluridine/tipiracil, the comparison of trifluridine/tipiracil to
regorafenib, and patient HRQL. Of note, all sensitivity analysis
scenarios produced for trifluridine/tipiracil versus regorafenib
showed trifluridine/tipiracil to be dominant, even when regorafenib
was assumed to have the same efficacy as trifluridine/tipiracil (owing
to the higher cost of regorafenib).
Sensitivity analysis results shown in Table 4 also demonstrate that
survival benefits observed for patients treated with trifluridine/
tipiracil versus BSC were consistent across pooled, phase III, and
phase II analyses. Mean OS improvement in each analysis was
calculated as 3.2, 3.0, and 4.4 months for the pooled, phase III, and
phase II analyses, respectively. Mean PFS improvement was also
reported similarly across each analysis, as 1.8, 1.5, and 2.1 months,
respectively.
Conclusion
Compared with the BSC, trifluridine/tipiracil is associated with a
mean improvement in OS of approximately 3.2 months. This
relatively large benefit, with an over 60% chance of achieving a
3-month survival gain, along with the small number of UK patients
with late-line mCRC, means that the end-of-life criteria set out by
NICE are satisfied. Compared with regorafenib, trifluridine/tipiracil
is associated with an improvement in OS of approximately 1.3
months, as well as an average cost saving of £6134 per patient.
Table 2 Survival Analysis Summary Results (All Studies)
Outcome
Clinical Trial Result, mos Model Result, mos
BSCa T/Ta Regob BSCa T/Ta Regob
OS
Median 5.4 7.3 6.4 5.3 7.5 6.9
RM 7.2 9.6 8.8 7.2 9.7 8.8
EM (D RM)c 7.9 (þ7.0%) 11.1 (þ10.1%) 9.8 (þ8.8%)
PFS
Median 1.7 1.9 1.9 1.7 2.6 2.6
RM 1.9 3.6 3.6 1.9 3.5 3.4
EM (D RM)c 1.9 (þ0.1%) 3.7 (þ5.7%) 3.7 (þ8.8%)
Abbreviations: BSC ¼ best supportive care; EM ¼ extrapolated mean; OS ¼ overall survival; PFS ¼ progression-free survival; Rego ¼ regorafenib; RM ¼ restricted mean; T/T ¼ trifluridine/tipiracil.
aT/T and BSC data taken from the pooled RECOURSE and phase II studies.
bRego data taken from the CORRECT study.
cThis outcome demonstrates the additional survival gained by extrapolating data beyond the observed period of the clinical trials.
Table 3 Base Case Model Results
Treatment
Total (95% Confidence Interval)
Costs QALYs LYs
BSC £9499 (£3911-£15,245) 0.40 (0.36-0.45) 0.66 (0.59-0.74)
T/T £17,978 (£12,385-£23,657) 0.57 (0.52-0.61) 0.92 (0.85-1.00)
Rego £24,112 (£17,924-£30,432) 0.51 (0.40-0.65) 0.82 (0.63-1.08)
Comparison
Incremental (95% Confidence Interval)
Costs QALYs LYs
T/T vs. BSC £8479 (£7959-£9011) 0.17 (0.11-0.22) 0.26 (0.16-0.37)
Rego vs. BSC £14,613 (£12,027-£17,642) 0.11 (0.01 to 0.26) 0.16 (0.05 to 0.43)
Rego vs. T/T £6134 (£3554-£9214) 0.06 (0.16 to 0.08) 0.10 (0.29 to 0.15)
Comparison Mean Cost per QALY Gained
Probability of Intervention Providing a Survival Gain of at
Least 3 Months
T/T vs. BSC £51,194 61.0%
Rego vs. BSC £133,561 22.5%
Rego vs. T/T T/T dominates 0.5%
T/T vs. Rego 7.6%
Abbreviations: BSC ¼ best supportive care; LY ¼ life year; QALY ¼ quality-adjusted life year; Rego ¼ regorafenib; T/T ¼ trifluridine/tipiracil.
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Table 4 Sensitivity Analysis Results
Scenario
BSC: Totals T/T: Totals Rego: Totals Mean Cost per QALY Gained
Costs QALYs LYs Costs QALYs LYs Costs QALYs LYs T/T vs. BSC Rego vs. BSC Rego vs. T/T
Base case £9499 0.40 0.66 £17,978 0.57 0.92 £24,112 0.51 0.82 £51,194 £133,561 T/T dominates
Population
RECOURSE £9498 0.39 0.65 £17,934 0.55 0.89 £23,822 0.49 0.79 £55,230 £145,958 T/T dominates




£9862 0.41 0.63 £18,212 0.54 0.83 £24,399 0.49 0.76 £63,270 £176,427 T/T dominates













£9499 0.40 0.66 £18,487 0.57 0.92 £24,112 0.51 0.82 £54,263 £133,561 T/T dominates
Abbreviations: BSA ¼ body surface area; BSC ¼ best supportive care; LY ¼ life year; mCRC ¼ metastatic colorectal cancer; NICE ¼ National Institute for Health and Care Excellence; OS ¼ overall survival; PFS ¼ progression-free survival; QALY ¼ quality-adjusted life year;
Rego ¼ regorafenib; STA ¼ single technology appraisal; T/T ¼ trifluridine/tipiracil.
aThis scenario uses the assumption of equal efficacy between T/T and Rego (ie, the same OS and PFS).
bThis scenario uses utilities from the previous NICE STA of cetuximab for the first-line treatment of mCRC.29





















The strengths of the analysis are the extent of the validation
conducted owing to the model having been used in a decision-
making context, and not having to rely on long-term extrapola-
tion for clinical outcomes such as OS and PFS (as follow-up of the
trifluridine/tipiracil clinical trials was sufficient to observe approxi-
mately 85% of deaths in the studies). The limitations of the analysis
relate to the lack of directly measured HRQL data for patients in
this line of disease, and assumptions made regarding the compara-
tive efficacy of regorafenib. These limitations were explored thor-
oughly within the sensitivity analysis to determine the potential
impact on model results, but uncertainty still remains as to the
applicability of data.
In summary, the results of this analysis confirm current clinical
opinion that trifluridine/tipiracil is an effective drug that provides
benefits to UK NHS patients with late-line mCRC, who maintain
good performance status and desire active treatment for their dis-
ease. When factoring in the discount scheme offered by Servier to
the NHS, NICE considered trifluridine/tipiracil a cost-effective use
of NHS resources, and recommended that it should be offered as a
treatment option for patients with late-line mCRC.12
Clinical Practice Points
 Trifluridine/tipiracil presents an important treatment option for
patients with late-line mCRC maintaining good performance
status, providing an OS improvement of over 3 months
compared with patients receiving BSC alone.
 When factoring in the discount scheme offered by Servier to the
NHS, trifluridine/tipiracil offers a cost-effective treatment option
versus BSC alone.
 Trifluridine/tipiracil dominates regorafenib with incremental LY
and QALY gains of 0.10 and 0.06, respectively; and a cost saving
of over £6000 per patient.
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